½ÃÀ庸°í¼­
»óǰÄÚµå
1402559

Á¦¹Ì±Û¸³Æ¾ ½ÃÀå : ÀǾàǰ À¯Çüº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, ȯÀÚ Àα¸ µ¿Åº°, Áö¿ªº°

Gemigliptin Market, By Type of Drug, By Distribution Channel, By End User, By Patient Demographics, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¦¹Ì±Û¸³Æ¾ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 17¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2030³â¿¡´Â 25¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2023-2030³âÀÇ CAGRÀº 5.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 17¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ÀÇ CAGR 5.40% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 25¾ï 9,000¸¸ ´Þ·¯
µµÇ¥ 1.¼¼°èÀÇ Á¦¹Ì±Û¸³Æ¾ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Gemigliptin Market-IMG1

Á¦¹Ì±Û¸³Æ¾Àº °­·ÂÇÏ°í ¼±ÅÃÀûÀÎ µðÆéƼµô ÆéƼµ¥ÀÌÁî-4(DPP-4) ¾ïÁ¦Á¦À̸ç, 2Çü ´ç´¢º´ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. µ¶Æ¯ÇÑ È­ÇÐ ±¸Á¶·Î ÀÎÇØ ÀÎÅ©·¹Æ¾ È£¸£¸óÀÇ ÀÛ¿ëÀ» °­È­ÇÏ¿© Ç÷´çÀ» È¿°úÀûÀ¸·Î ³·Ãä´Ï´Ù. ÀÌ °æ±¸¿ë ¾à¹°Àº Æ÷µµ´ç ÀÇÁ¸Àû Àν¶¸° ºÐºñ¸¦ ÃËÁøÇÏ°í ±Û·çÄ«°ï ¹æÃâÀ» ¾ïÁ¦ÇÏ¿© Ç÷´ç Á¶Àý¿¡ À¯¸ÁÇÑ °á°ú¸¦ °¡Á®¿É´Ï´Ù.DPP-4 ¾ïÁ¦Á¦ °è¿­ÀÇ »õ·Î¿î ¾à¹°ÀÎ Á¦¹Ì±Û¸³Æ¾ÀÇ ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú È¿´ÉÀº Ç÷´ç Á¶ÀýÀ» °³¼±Çϰí ÀúÇ÷´ç À§Çè °¨¼Ò¸¦ Ç÷´ç Á¶Àý °³¼±°ú ÀúÇ÷´ç À§Çè °¨¼Ò¸¦ ¿øÇÏ´Â ´ç´¢º´ ȯÀڵ鿡°Ô À¯¿ëÇÑ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¾à¹°Àº µ¶Æ¯ÇÑ È­ÇÐ ±¸Á¶¿Í ÀÛ¿ë±âÀüÀ¸·Î ÀÎÇØ ´Ù¸¥ Ç×´ç´¢º´ ¾à¹°°ú Â÷º°È­µË´Ï´Ù. ÀϹÝÀûÀ¸·Î 1ÀÏ 1ȸ °æ±¸¿ë Ä¡·áÁ¦·Î ó¹æµÇ´Â Á¦¹Ì±Û¸³Æ¾Àº ´ç´¢º´À» °ü¸®Çϴ ȯÀڵ鿡°Ô ÆíÀǼºÀ» Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸, Àü·«Àû ¸¶ÄÉÆÃ, Á¦Çü ¹× º´¿ë¿ä¹ýÀÇ ÀáÀçÀû Çõ½ÅÀ» ÅëÇØ Á¦¹Ì±Û¸³Æ¾Àº ´Ù¾çÇÑ ´ç´¢º´ °ü¸® »óȲ¿¡¼­ °¡Ä¡ ÀÖ´Â ´ë¾ÈÀ¸·Î ÀÚ¸®¸Å±èÇÒ ¼ö ÀÖµµ·Ï ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

´ç´¢º´ À¯º´·ü Áõ°¡, ´ç´¢º´¿¡ ´ëÇÑ ÀÎ½Ä ¹× Áø´Ü °³¼±, °æ±¸¿ë Ç×´ç´¢º´Á¦·ÎÀÇ ÀüȯÀº ¿¹Ãø ±â°£ Áß ¼¼°è Á¦¹Ì±Û¸³Æ¾ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¾çÈ£ÇÑ ±ÔÁ¦ ȯ°æµµ ¿¹Ãø ±â°£ Áß ¼¼°è Á¦¹Ì±Û¸³Æ¾ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÈï ½ÃÀå¿¡¼­ÀÇ È®Àå, º´¿ë ¿ä¹ý, ȯÀÚ Á᫐ Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ ÃÊÁ¡, ¼Ò¾Æ ¹× Àӽżº ´ç´¢º´¿¡ ´ëÇÑ »ç¿ëÀº ¿¹Ãø ±â°£ Áß ¼¼°è Á¦¹Ì±Û¸³Æ¾ ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ±âÁ¸ ÀǾàǰ°úÀÇ °æÀï, ƯÇã ¸¸·á, Á¦³×¸¯ ÀǾàǰ°úÀÇ °æÀï, ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á´Â ¿¹Ãø ±â°£ Áß Á¦¹Ì±Û¸³Æ¾ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â Á¦¹Ì±Û¸³Æ¾ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí 2022³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦½ÃÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú ¹× Àü·«°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î Á¦¹Ì±Û¸³Æ¾ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • Á¦¹Ì±Û¸³Æ¾ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â Á¦¹Ì±Û¸³Æ¾ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
  • ´ç´¢º´ À¯º´·üÀÇ »ó½Â
    • ¾ïÁ¦¿äÀÎ
  • ±âÁ¸ÀÇ ÀǾàǰ°úÀÇ °æÀï
    • ±âȸ
  • ½ÅÈï ½ÃÀå¿¡¼­ÀÇ È®´ë
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃøÀÇ ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå, ÀǾàǰ À¯Çüº°, 2018-2030³â

  • Á¦¹Ì±Û¸³Æ¾ ´ÜÀÏ¿ä¹ý
  • Á¦¹Ì±Û¸³Æ¾ º´¿ë¿ä¹ý

Á¦6Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

  • º´¿ø
  • ¼Ò¸ÅÁ¡ ¹× ¿Ü·¡ ½Ã¼³
  • ±âŸ(Çмú¿¬±¸±â°ü)

Á¦8Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå, ȯÀÚ Àα¸ µ¿Åº°, 2018-2030³â

  • ¼ºÀÎ
  • °í·ÉÀÚ

Á¦9Àå Á¦¹Ì±Û¸³Æ¾ ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦10Àå °æÀï ±¸µµ

  • Daewoong Pharmaceutical
  • Sanofi
  • LG Chem
  • Hanmi Pharmaceutical Co., Ltd.
  • Merck

Á¦11Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 24.01.15

The global gemigliptin market size was valued at US$ 1.79 Bn in 2023 and is expected to reach US$ 2.59 Bn by 2030, grow at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 1.79 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.40% 2030 Value Projection: US$ 2.59 Bn
Figure 1. Global Gemigliptin Market Share (%), by Region, 2023
Gemigliptin Market - IMG1

Gemigliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. With its unique chemical structure, gemigliptin effectively lowers blood glucose levels by enhancing the action of incretin hormones. This oral medication offers promising results in gycemic control by promoting glucose-dependent insulin secretion and suppressing glucagon release. As a newer entrant in the DPP-4 inhibitor class, Gemigliptin's safety profile and efficacy make it a valuable option for diabetes patients seeking improved glucose regulation and a reduced risk of hypoglycaemia. This medication is characterized by its unique chemical structure and mechanism of action, setting it apart from other antidiabetic drugs. Gemigliptin is typically prescribed as a once-daily oral treatment, providing convenience for patients managing their diabetes. However, ongoing research, strategic marketing, and potential innovations in formulation or combination therapies aim to position gemigliptin as a valuable option in the diverse landscape of diabetes management.

Market Dynamics:

The rising prevalence of diabetes, increasing awareness and diagnosis, and shift towards oral antidiabetic drugs are anticipated to drive growth of the global gemigliptin market over the forecast period. Moreover, a favorable regulatory environment is also expected to boost the growth of the global gemigliptin market over the forecast period. Expansion in emerging markets, combination therapies, a focus on patient-centric approaches, pediatric use, and gestational diabetes are expected to create growth opportunities for the global gemigliptin market during the forecast period.

However, competition from established drugs, patent expiry, generic competition, and safety concerns are expected to hamper growth of the gemigliptin market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the gemigliptin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the gemigliptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Daewoong Pharmaceutical, Sanofi, LG Chem, Hanmi Pharmaceutical Co., Ltd., and Merck
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The gemigliptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the gemigliptin market

Detailed Segmentation:

  • Gemigliptin Market Segmentation, By Type of Drug:
    • Gemigliptin Monotherapy
    • Gemigliptin Combination Therapy
  • Gemigliptin Market Segmentation, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Gemigliptin Market Segmentation, By End User:
    • Hospitals
    • Clinics and Outpatient Facilities
    • Others (Academic and Research Institutes)
  • Gemigliptin Market Segmentation, By Patient Demographics:
    • Adult Population
    • Geriatric Population
  • Gemigliptin Market Segmentation, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profile:
    • Daewoong Pharmaceutical
    • Sanofi
    • LG Chem
    • Hanmi Pharmaceutical Co., Ltd.
    • Merck

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Gemigliptin , By Type of Drug
    • Market Gemigliptin , By Distribution Channel
    • Market Gemigliptin , By End User
    • Market Gemigliptin , By Patient Demographics
    • Market Gemigliptin , By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Rising prevalence of diabetes
    • Restraints
  • Competition from established drugs
    • Opportunities
  • Expansion in emerging markets
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Gemigliptin Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Gemigliptin Market , By Type of Drug, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Gemigliptin Monotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Gemigliptin Combination Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Gemigliptin Market , By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Gemigliptin Market , By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Clinics and Outpatient Facilities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others (Academic and Research Institutes)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Gemigliptin Market , By Patient Demographics, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Adult Population
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Geriatric Population
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Gemigliptin Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Daewoong Pharmaceutical
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • LG Chem
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Hanmi Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Merck
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦